Nasdaq · CIK 0001680581
FULC Fulcrum Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jun 30, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Signals
Open-market buys and sells at Fulcrum Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Greg Tourangeau Principal Accounting Officer sell | $2,520 498 shares | -3% | - |
Transactions
The last 14 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 26, 2025 | Sonja Banks director | AGrant or award Stock Option (right to buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Jun 30, 2025 |
| Jun 26, 2025 | Katina Dorton director | AGrant or award Stock Option (right to buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Jun 30, 2025 |
| Jun 26, 2025 | Alan Ezekowitz director | AGrant or award Stock Option (right to buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Jun 30, 2025 |
| Jun 26, 2025 | Robert J Gould director | AGrant or award Stock Option (right to buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Jun 30, 2025 |
| Jun 26, 2025 | Colin Hill director | AGrant or award Stock Option (right to buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Jun 30, 2025 |
| Jun 26, 2025 | Kate Haviland director | AGrant or award Stock Option (right to buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Jun 30, 2025 |
| Jun 26, 2025 | James A Geraghty director | AGrant or award Stock Option (right to buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Jun 30, 2025 |
| Jun 26, 2025 | Rachel K. King director | AGrant or award Stock Option (right to buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Jun 30, 2025 |
| May 8, 2025 | Greg Tourangeau Principal Accounting Officer | SOpen-market sale Common Stock | -498 | $5.06 | $2,520 | 14,062 | May 9, 2025 |
| Jan 24, 2025 | Curtis Gale Oltmans Chief Legal Officer | AGrant or award Stock Option (right to buy)derivative | +225,000 | $0.00 | $0 | 225,000 | Jan 28, 2025 |
| Jan 24, 2025 | Greg Tourangeau Principal Accounting Officer | AGrant or award Stock Option (right to buy)derivative | +76,120 | $0.00 | $0 | 76,120 | Jan 28, 2025 |
| Jan 24, 2025 | Alex Sapir See Remarks | AGrant or award Stock option - Right to Buyderivative | +582,000 | $0.00 | $0 | 582,000 | Jan 28, 2025 |
| Jan 24, 2025 | Alan A Musso Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +285,000 | $0.00 | $0 | 285,000 | Jan 28, 2025 |
| Nov 12, 2024 | Rachel K. King director | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Nov 14, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Sonja Banksdirector
- Katina Dortondirector
- Alan Ezekowitzdirector
- James A Geraghtydirector
- Robert J Goulddirector
- Kate Havilandceo, officer, director
- Colin Hilldirector
- Rachel K. Kingdirector
- Alan A MussoChief Financial Officer
- Curtis Gale OltmansChief Legal Officer
- Alex SapirSee Remarks
- Greg TourangeauPrincipal Accounting Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.